Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib
- 15 September 2015
- journal article
- Published by Springer Nature in Leukemia
- Vol. 29 (12) , 2402-2404
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Direct Comparison of Flow-FISH and qPCR as Diagnostic Tests for Telomere Length Measurement in HumansPLOS ONE, 2014
- Epigenetic aging upon allogeneic transplantation: the hematopoietic niche does not affect age-associated DNA methylationLeukemia, 2014
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- The telomere syndromesNature Reviews Genetics, 2012
- Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutationAnnals of Hematology, 2012
- Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapyHematological Oncology, 2009
- Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem CellsStem Cells, 2007
- Telomere Shortening Correlates with Prognostic Score at Diagnosis and Proceeds Rapidly during Progression of Chronic Myeloid LeukemiaLeukemia & Lymphoma, 2004
- Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid LeukemiaAnnals of the New York Academy of Sciences, 2003
- Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemiaBlood, 2003